About

Podcasts

Author Interview: Professor Dennis McGonagle, 2024

Publications

Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

Publications

"I couldn't carry on taking a drug like that": A qualitative study of patient perspectives on side effects from rheumatology drugs

Publications

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: A post hoc analysis of a Phase 3b/4 randomised safety study

Podcasts

Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvements between DMARDs

Publications

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Real-world data from the BIOBADASER registry

Podcasts

Author Interview: Dr Jürgen Rech, 2024

Podcasts

Discussing PsA: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population

Podcasts

Discussing RA: March 2024

Publications

Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: A real-world clinical context multicenter study

Publications

Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-Year data from SELECT-COMPARE

Publications

Long-term etanercept response for patients with radiographic axial spondyloarthritis based on achievement of early, intermediate, or late responses during index studies

Publications

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials

Podcasts

Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment

Publications

Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients

Publications

Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

Podcasts

Discussing RA: February 2024

Podcasts

Discussing PsA: Clinical Response to Guselkumab & Sequential Lines of b/tsDMARDs

Publications

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial

Publications

Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): Data from the French Multicentre Retrospective FORSYA Study

Publications

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Publications

Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

Podcasts

Author Interview: Professor Andrea Rubbert-Roth, 2023

Publications

Comparative Effectiveness of Tofacitinib and Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis in Real-world Practice: A Prospective Observational Study

Publications

Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis

Publications

Abatacept in Individuals at High Risk of Rheumatoid Arthritis (APIPPRA): A Randomised, Double-blind, Multicentre, Parallel, Placebo-controlled, Phase 2b Clinical Trial

Publications

Long term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: A post hoc analysis of final safety data from 25 randomized clinical trials

Publications

Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years

Publications

Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis

Publications

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Publications

Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

Publications

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, Phase 3 trial